Clinical Trial Monitoring
Smarter monitoring for today’s clinical trials
Clinical trial monitoring is becoming more complex as protocols evolve and data sources expand. Sponsors need flexible approaches that help teams focus on the activities that matter most. Our clinical trial monitoring approach combines experienced clinical research associates (CRAs) with technology-enabled methods that support efficient source data verification (SDV), source data review (SDR) and oversight across studies. Our CRAs strengthen site engagement, support protocol compliance, identify risks early on and maintain clear communication across stakeholders. Scalable digital capabilities further support targeted sampling strategies, reduce manual tracking burdens and improve visibility into monitoring activities.
Learn more about our clinical trial monitoring services
A structured, flexible solution that drives better data quality and operational success.
Technology-enabled oversight with a monitoring application
To support more efficient and adaptable monitoring, the PPD™ clinical research business of Thermo Fisher Scientific offers proprietary digital capabilities such as the Monitoring Application (MApp). Designed as a scalable, system-agnostic solution, MApp helps teams manage subject data sampling activities across both electronic data capture (EDC) and non-EDC data sources. The platform supports flexible sampling at multiple levels, including subject, visit and form, and allows target percentages to be adjusted as study requirements evolve. Used alongside experienced CRAs, MApp helps sponsors streamline SDV and SDR activity management, strengthen documentation and support more focused, risk-informed monitoring approaches.
Advance monitoring efficiency with flexible support
From experienced CRAs and strong site engagement to technology-enabled support for SDV and SDR activities, we help sponsors build monitoring approaches aligned to study needs. Our clinical trial monitoring solutions combine clinical oversight, operational consistency and digital enablement to support quality, compliance and efficiency across Phase II–IV studies.